Silicon Valley's longevity movement confronts scientific limits as Bryan Johnson halts Rapamycin use
By
Skye Jacobs
Summary
Silicon Valley's longevity movement is facing a reality check as key figures confront the limits of anti-aging science. Bryan Johnson stopped taking Rapamycin in September 2024 after years of self-experimentation, signaling a broader retreat from the hype surrounding longevity drugs. The article examines how the movement's promises have yet to be substantiated by rigorous science, and how even its most devoted proponents are beginning to acknowledge the gap between ambition and evidence.
Source
Key quotes
· 3 pulledThe most revealing development in Silicon Valley's longevity movement is not a new compound or breakthrough protocol, but a retreat.
Bryan Johnson, the tech entrepreneur who turned his body into a public experiment, stopped taking Rapamycin in September 2024 after several years of self-testing the drug.
That shift comes as some of the movement's most prominent figures begin confronting the limits of a science that has yet to live up to the hype.
You might also wanna read
Biohacker Bryan Johnson claims Australia trip aged him 13 years after breaking anti-ageing rules
Multimillionaire biohacker Bryan Johnson, who spends $2 million annually on anti-ageing treatments, claims a trip to Australia to meet his g
Satirical piece mocks Bryan Johnson's anti-aging regimen with sperm-and-egg claim
A satirical article about tech multimillionaire Bryan Johnson, known for his extreme anti-aging regimen Project Blueprint, claiming he has r
Mastodon post critiques Nature article on tech billionaire life extension methods
A post on Mastodon shares and comments on a Nature article about tech billionaires pursuing life extension through body hacking. The poster
How the Ultra-Rich Are Pursuing Immortality Through Science and Technology
The article explores how wealthy and powerful individuals — from historical emperors to modern Silicon Valley billionaires — are increasingl

Comments
Sign in to join the conversation.
No comments yet. Be the first.